Breaking !
News today that Galderma has succeeded in gaining FDA Approval for Mirvaso – the brand name chosen for the product that during development was known as Sansrosa, CD07805/47 and Col-118.
The Brimonidine Tartrate 0.33% Topical Gel is expected to be available as soon as next month.
Read more about Mirvaso.
